Table 5.
GO Enrichment and Pathway Analyses of Differentially Expressed Genes
| GO Term | Gene Count |
P-Value | Genes |
|---|---|---|---|
| Biological process | |||
| Regulation of immune response | 17 | 3.76E-12 |
ICAM1, IGLV1-44, IGKV5-2, NCR1, IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV2-23, IGKV4-1, KLRF1,TREM1, KIR2DL3, TREML1, IGLC2, KLRD1, and IGKV3-15 |
| Receptor-mediated endocytosis | 16 | 8.68E-11 |
LDLR, IGLV1-44, IGKV5-2, JCHAIN, SPARC, IGLV2-11, IGLV2-8, IGLV3-19, CTTN, IGKV1-5, IGLV2-23, IGKV4-1, IGLC2, LRP3, CD14, and IGKV3-15 |
| Complement activation | 11 | 4.37E-09 | IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, CLU, IGKV4-1, IGLC2, and IGKV3-15 |
| Immune response | 20 | 4.97E-09 |
IL18R1, TNF, IL18RAP, CXCL5, IGLV1-44, IGKV5-2, JCHAIN, FASLG, PF4, IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, PPBP, FCAR, IGLV2-23, IGKV4-1, IL1B, KIR2DL3, and IGKV3-15 |
| Complement activation and classical pathway | 11 | 1.56E-08 | IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, CLU, IGKV4-1, IGLC2, and IGKV3-15 |
| Platelet activation | 10 | 7.55E-07 |
VWF, GP6, F5, C6ORF25, PF4, GP1BA, ITGB3, TREML1, CLEC1B, and GP9 |
| Fc-γ receptor signaling pathway involved in phagocytosis | 10 | 1.74E-06 | IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Platelet degranulation | 9 | 3.36E-06 | VWF, APP, F5, PPBP, CLU, PF4, SPARC, ITGB3, and ITGA2B |
| Blood coagulation | 11 | 5.08E-06 |
PRKAR2B, VWF, GP6, F5, C6ORF25, PDGFC, GP1BA, PDGFD, ITGB3, GP9, and PLAUR |
| FCERI signaling pathway | 10 | 2.71E-05 | IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Positive regulation of nitric oxide biosynthetic process | 6 | 3.54E-05 | ICAM1, TNF, CLU, IL1B, PTX3, and KLF4 |
| Proteolysis | 14 | 0.000 |
NRIP3, IGLV1-44, IGKV5-2, ANPEP, MMP25, IGLV2-11, IGKV1-5, IGLV3-19, IGLV2-8, F5, IGLV2-23, IGKV4-1, IGLC2, and IGKV3-15 |
| Inflammatory response | 12 | 0.001 |
SDC1, TNF, IL18RAP, PPBP, CXCL5, ANXA1, IL1B, PF4, PTX3, NLRP3, CD14, and MMP25 |
| Antibacterial humoral response | 5 | 0.001 | APP, ADM, HIST2H2BE, HIST1H2BJ, and JCHAIN |
| Positive regulation of cell division | 5 | 0.001 | TAL1, PPBP, IL1B, PDGFC, and PDGFD |
| Innate immune response | 12 | 0.001 |
APP, CLU, ANXA1, JCHAIN, PADI4, TREM1, PTX3, NLRP3, IGLC2, TREML1, KLRD1, and CD14 |
| ECM organization | 8 | 0.002 | ICAM1, VWF, APP, TNF, ITGB5, SPARC, ITGB3, and ITGA2B |
| Response to glucocorticoid | 5 | 0.003 | SDC1, TNF, ADM, SPARC, and ADAM9 |
| Response to lipopolysaccharide | 7 | 0.003 | PPBP, ADM, CXCL5, FASLG, PF4, SPARC, and TRIB1 |
| Positive regulation of chemokine biosynthetic process | 3 | 0.003 | EGR1, TNF, and IL1B |
| Negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 4 | 0.004 | TNF, MCL1, IL1B, and PF4 |
| Viral entry into host cell | 5 | 0.005 | ICAM1, LDLR, ITGB5, ANPEP, and ITGB3 |
| Response to yeast | 3 | 0.006 | APP, ADM, and PTX3 |
| Defense response to Gram-positive bacterium | 5 | 0.007 | APP, TNF, ADM, HIST2H2BE, and HIST1H2BJ |
| Negative regulation of gene expression | 6 | 0.007 | TNF, LDLR, GAS2L1, ZNF503, MYADM, and KLF4 |
| Cell adhesion mediated by integrin | 3 | 0.007 | ICAM1, ITGB3, and ADAM9 |
| Positive regulation of membrane protein ectodomain proteolysis | 3 | 0.007 | TNF, IL1B, and ADAM9 |
| Positive regulation of IFN-γ production | 4 | 0.008 | IL18R1, TNF, IL1B, and CD14 |
| Cell surface receptor signaling pathway | 8 | 0.01 |
IL18RAP, ANXA1, GP1BA, TSPAN9, KLRF1, KLRD1, CD14, and CLEC1B |
| Blood coagulation, intrinsic pathway | 3 | 0.011 | VWF, GP1BA, and GP9 |
| Positive regulation of leukocyte chemotaxis | 3 | 0.011 | PPBP, CXCL5, and PF4 |
| Integrin-mediated signaling pathway | 5 | 0.011 | C6ORF25, ITGB5, ITGB3, ADAM9, and ITGA2B |
| Platelet formation | 3 | 0.012 | TAL1, C6ORF25, and CLEC1B |
| Positive regulation of transcription from RNA polymerase II promoter | 17 | 0.012 | EGR1, NAMPT, TNF, EGR2, ABLIM3, PF4, MYBL1, NLRP3, AHR, TAL1, APP, SPX, BHLHA15, IL1B, MAML3, FOSL1, and KLF4 |
| Cellular response to hydrogen peroxide | 4 | 0.014 | IL18RAP, ANXA1, PDGFD, and KLF4 |
| Positive regulation of NF-kB import into the nucleus | 3 | 0.014 | IL18R1, TNF, and IL1B |
| Positive regulation of MAPK activity | 4 | 0.015 | TNF, PDE5A, PDGFC, and PDGFD |
| Positive regulation of smooth muscle cell proliferation | 4 | 0.016 | NAMPT, TNF, PDGFD, and ALOX12 |
| Cellular response to lipopolysaccharide | 5 | 0.017 | ICAM1, TNF, NLRP3, CD14, and ADAM9 |
| Regulation of gastric acid secretion | 2 | 0.017 | SGK1 and KCNQ1 |
| Cell adhesion | 10 | 0.02 | ICAM1, VWF, APP, SCN1B, ITGB5, GP1BA, ITGB3, ADAM9, GP9, and ITGA2B |
| Leukocyte migration | 5 | 0.022 | ICAM1, GP6, ESAM, TREM1, and ITGB3 |
| Regulation of cell proliferation | 6 | 0.024 | TAL1, SGK1, TNF, PPBP, ANXA1, and PF4 |
| Establishment or maintenance of microtubule cytoskeleton polarity | 2 | 0.026 | KIF2C and LMNA |
| positive regulation of calcidiol 1-monooxygenase activity | 2 | 0.026 | TNF and IL1B |
| Positive regulation of phagocytosis | 3 | 0.026 | TNF, IL1B, and PTX3 |
| Positive regulation of gene expression | 7 | 0.028 | TNF, LDLR, ID1, IL1B, PF4, KLF4, and ALOX12 |
| Positive regulation of NF-kB transcription factor activity | 5 | 0.03 | ICAM1, TNF, CLU, IL1B, and NLRP3 |
| Lipopolysaccharide-mediated signaling pathway | 3 | 0.032 | TNF, IL1B, and CD14 |
| Sequestering of triglyceride | 2 | 0.035 | TNF and IL1B |
| IL-1 beta production | 2 | 0.043 | IL1B and NLRP3 |
| Positive regulation of fever generation | 2 | 0.043 | TNF and IL1B |
| Cell matrix adhesion | 4 | 0.044 | ITGB5, ITGB3, ADAM9, and ITGA2B |
| TGFβ receptor signaling pathway | 4 | 0.047 | ID1, CLDN5, ITGB5, and ADAM9 |
| Positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 3 | 0.048 | TNF, NLRP3, and ALOX12 |
| Positive regulation of apoptotic process | 7 | 0.049 | TNF, ADM, CLU, FASLG, FOSL1, MELK, and DUSP6 |
| Platelet aggregation | 3 | 0.049 | GP1BA, ITGB3, and ITGA2B |
| Cellular component | |||
| Plasma membrane | 68 | 4.45E-09 |
SEPT5, IGLV1-44, LDLR, C6ORF25, CLDN5, FASLG, IGKV1-12, TSPAN9, MMP25, GLDC, GP9, ATP2B1, PRKAR2B, CTTN, APP, GP6, HOMER3, IGLV2-23, ZNF185, DLG3, PDGFC, ESAM, FAM129B, KLRD1, KCNQ1, ICAM1, SGK1, IL18RAP, SLCO4A1, WLS, NCR1, MYADM, PLAUR, IGLV2-11, IGKV1-5, SDC1, F5, COLQ, IGKV4-1, TREM1, KIR2DL3, EMP1, MELK, CLEC1B, ITGA2B, TNF, SCN1B, CALD1, IGKV5-2, ITGB5, GNG11, ITGB3, C2ORF88, IGLV2-8, IGLV3-19, GP1BA, KLRF1, IGKV3-15, IL18R1, ANXA1, SPARC, RAPH1, AQP10, FCAR, CPNE2, IGLC2, TREML1, and CD14 |
| Extracellular region | 34 | 1.16E-06 | LTBP1, SCN1B, TNF, IGLV1-44, CXCL5, IGKV5-2, CLU, JCHAIN, FASLG, PF4, IGKV1-12, IGLV2-8, APP, IGLV3-19, IGLV2-23, IL1B, PDGFC, PDGFD, PTX3, IGKV3-15, ANXA1, SPARC, NLRP3, IGLV2-11, VWF, IGKV1-5, F5, ADM, FCAR, PPBP, IGKV4-1, TREM1, IGLC2, and CD14 |
| Extracellular space | 30 | 2.25E-06 | NAMPT, TNF, CXCL5, FAM20C, CLU, JCHAIN, FASLG, PF4, ANPEP, APP, SPX, HIST1H2BJ, IL1B, DLG3, PDGFC, PDGFD, PTX3, ADAM9, ICAM1, ANXA1, SPARC, F5, PPBP, ADM, COLQ, HIST2H2BE, FRMD4B, IGLC2, CD14, and CMTM5 |
| Platelet alpha granule lumen | 7 | 6.55E-06 | VWF, APP, F5, PPBP, CLU, PF4, and SPARC |
| Cell surface | 17 | 1.34E-05 |
ICAM1, TNF, LDLR, CLU, ANXA1, ITGB5, SPARC, and ITGB3, APP, SDC1, GP6, GP1BA, PDGFC, TREML1, INTU, ITGA2B, and ADAM9 |
| Extracellular exosome | 44 | 4.28E-05 |
HIST1H2AC, NAMPT, CLU, FAM20C, CLDN5, JCHAIN, FASLG, ITGB5, ANPEP, ITGB3, ATP2B1, PRKAR2B, CTTN, APP, IGLV3-19, GP6, PGRMC1, IL1B, PDGFC, ESAM, GP1BA, FAM129B, PDGFD, TUBA1A, TUBB1, ADAM9, ICAM1, ANXA1, WLS, MYADM, PLAUR, IGLV2-11, PDZK1IP1, VWF, IGKV1-5, SDC1, HIST2H2BE, SH3BGRL2, CPNE2, IGLC2, CD14, XYLB, ALOX12, and ITGA2B |
| Membrane raft | 9 | 3.55E-04 |
ATP2B1, PRKAR2B, ICAM1, APP, TNF, SDPR, KCNQ1, MYADM, and CD14 |
| External side of the plasma membrane | 9 | 4.43E-04 |
ICAM1, SDC1, TNF, LDLR, FASLG, ANPEP, IGLC2, KLRD1, and ITGA2B |
| Focal adhesion | 11 | 0.002 |
ICAM1, SDC1, CTTN, ZNF185, ANXA1, ITGB5, TSPAN9, ITGB3, ADAM9, PLAUR, and ITGA2B |
| Blood microparticle | 7 | 0.002 |
IGKV1-5, CLU, JCHAIN, IGKV4-1, IGLC2, IGKV3-15, and ITGA2B |
| Platelet alpha granule membrane | 3 | 0.005 | SPARC, ITGB3, and ITGA2B |
| Platelet alpha granule | 3 | 0.006 | VWF, SPARC, and TREML1 |
| Integral component of the plasma membrane | 22 | 0.008 |
ICAM1, TNF, LDLR, SLCO4A1, FASLG, ANPEP, TSPAN9, ITGB3, NCR1, AQP10, PLAUR, GP9, ATP2B1, APP, SDC1, GP6, FCAR, GP1BA, KLRF1, KIR2DL3, CLEC1B, and ITGA2B |
| Phagocytic cup | 3 | 0.011 | TNF, PEAR1, and ANXA1 |
| Clathrin-coated pit | 4 | 0.011 | APP, CTTN, LDLR, and LRP3 |
| Anchored component of the external side of the plasma membrane | 3 | 0.014 | GGTA1P, GP1BA, and CD14 |
| Basolateral plasma membrane | 6 | 0.018 | ATP2B1, LDLR, ANXA1, DLG3, KCNQ1, and ADAM9 |
| Integrin complex | 3 | 0.021 | ITGB5, ITGB3, and ITGA2B |
| Receptor complex | 5 | 0.022 | APP, LDLR, ITGB5, ITGB3, and KLRD1 |
| Dendritic shaft | 3 | 0.029 | PRKAR2B, APP, and DLG3 |
| Cytoplasm | 55 | 0.043 |
NAMPT, MCM10, ISG20, PRKAR2B, CTTN, APP, HOMER3, SDPR, ZNF185, HIST1H2BJ, DLG3, PIWIL2, PDGFC, FAM129B, TUBB1, KCNQ1, EGR1, SGK1, EGR2, PADI4, UBE2C, NLRP3, AHR, SH2D2A, SDC1, ADM, HIST2H2BE, FRMD4B, PPP1R15A, INTU, XYLB, ALOX12, MCL1, ABLIM3, CLU, TRIB1, SPATS2, NCAPG, RNF165, STRIP2, SKA3, GP1BA, HRASLS2, ANXA1, LMNA, CDC20, SPARC, RAPH1, SH3BGRL2, GAS2L1, CPNE2, RFX2, TREML1, KLF4, and DUSP6 |
| Molecular function | |||
| Antigen binding | 12 | 1.30E-09 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, JCHAIN, IGKV4-1, KIR2DL3, IGLC2, and IGKV3-15 |
| Receptor activity | 11 | 1.82E-05 |
ICAM1, IL18R1, GP6, IL18RAP, LDLR, ITGB5, ANPEP, TREM1, ITGB3, KIR2DL3, and PLAUR |
| Serine-type endopeptidase activity | 11 | 7.17E-05 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, F5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Virus receptor activity | 5 | 0.003 | ICAM1, LDLR, ITGB5, ANPEP, and ITGB3 |
| Platelet-derived GF receptor binding | 3 | 0.007 | PDGFC, PDGFD, and ITGB3 |
| Collagen binding | 4 | 0.015 | VWF, GP6, SPARC, and ADAM9 |
| ECM binding | 3 | 0.021 | SPARC, ITGB3, and ITGA2B |
| IgA binding | 2 | 0.026 | FCAR and JCHAIN |
| Pathway | |||
| KEGG pathway | |||
| ECM‒receptor interaction | 8 | 4.38E-05 | VWF, SDC1, GP6, ITGB5, GP1BA, ITGB3, GP9, and ITGA2B |
| Hematopoietic cell lineage | 8 | 4.38E-05 | TNF, IL1B, ANPEP, GP1BA, ITGB3, CD14, GP9, and ITGA2B |
| African trypanosomiasis | 4 | 0.006 | ICAM1, TNF, IL1B, and FASLG |
| Pertussis | 5 | 0.009 | TNF, CXCL5, IL1B, NLRP3, and CD14 |
| Hypertrophic cardiomyopathy | 5 | 0.011 | TNF, LMNA, ITGB5, ITGB3, and ITGA2B |
| NK cell‒mediated cytotoxicity | 6 | 0.011 | ICAM1, TNF, FASLG, KIR2DL3, NCR1, and KLRD1 |
| PI3K‒Akt signaling pathway | 10 | 0.013 |
VWF, SGK1, MCL1, ITGB5, FASLG, GNG11, PDGFC, PDGFD, ITGB3, and ITGA2B |
| Dilated cardiomyopathy | 5 | 0.014 | TNF, LMNA, ITGB5, ITGB3, and ITGA2B |
| Platelet activation | 6 | 0.014 | VWF, GP6, GP1BA, ITGB3, GP9, and ITGA2B |
| Malaria | 4 | 0.017 | ICAM1, SDC1, TNF, and IL1B |
| Cytokine‒cytokine receptor interaction | 8 | 0.017 | IL18R1, TNF, IL18RAP, PPBP, CXCL5, IL1B, FASLG, and PF4 |
| Pathogenic E. coli infection | 4 | 0.018 | CTTN, TUBB1, TUBA1A, and CD14 |
| Proteoglycans in cancer | 7 | 0.023 | SDC1, CTTN, TNF, ITGB5, FASLG, ITGB3, and PLAUR |
| Phagosome | 6 | 0.025 | FCAR, ITGB5, ITGB3, TUBB1, TUBA1A, and CD14 |
| Inflammatory bowel disease | 4 | 0.033 | IL18R1, TNF, IL18RAP, and IL1B |
| Arrhythmogenic right ventricular cardiomyopathy | 4 | 0.037 | LMNA, ITGB5, ITGB3, and ITGA2B |
| Reactome pathway | |||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 17 | 2.07E-10 |
ICAM1, IGLV1-44, IGKV5-2, NCR1, IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV2-23, IGKV4-1, KLRF1, TREM1, KIR2DL3, TREML1, IGLC2, KLRD1, and IGKV3-15 |
| Scavenging of heme from plasma | 11 | 4.03E-09 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, JCHAIN, IGKV4-1, IGLC2, and IGKV3-15 |
| CD22-mediated B-cell receptor regulation | 10 | 2.14E-08 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| FCERI signaling | 10 | 2.14E-08 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Classical antibody-mediated complement activation | 10 | 3.31E-08 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 10 | 8.38E-08 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| FCGR activation | 10 | 7.38E-08 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Initial triggering of complement | 10 | 1.36E-07 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Role of phospholipids in phagocytosis | 10 | 3.31E-07 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| FCERI-mediated Ca2+ mobilization | 10 | 5.49E-07 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| FCERI-mediated MAPK activation | 10 | 4.97E-07 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Antigen activates B-cell receptor leading to the generation of second messengers | 10 | 8.82E-07 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Regulation of actin dynamics for phagocytic cup formation | 10 | 6.50E-06 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| CERI-mediated NF-kB activation | 10 | 2.18E-05 |
IGLV2-11, IGLV2-8, IGLV3-19, IGKV1-5, IGLV1-44, IGLV2-23, IGKV5-2, IGKV4-1, IGLC2, and IGKV3-15 |
| Platelet degranulation | 9 | 1.01E-04 | VWF, APP, F5, PPBP, CLU, PF4, SPARC, ITGB3, and ITGA2B |
| Platelet adhesion to exposed collagen | 4 | 5.69E-04 | VWF, GP6, GP1BA, and GP9 |
| GP1b-IX-V activation signaling | 3 | 0.005 | VWF, GP1BA, and GP9 |
| Mitotic prometaphase | 6 | 0.007 | SPC24, KIF2C, CDC20, AURKB, TUBB1, and TUBA1A |
| ECM proteoglycans | 5 | 0.01 | APP, ITGB5, SPARC, ITGB3, and ITGA2B |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 3 | 0.012 | SPC24, KIF2C, CDC20, AURKB, TUBB1, and TUBA1A |
| p130Cas linkage to MAPK signaling for integrins | 3 | 0.012 | VWF, ITGB3, and ITGA2B |
| Resolution of Sister Chromatid Cohesion | 6 | 0.012 | VWF, ITGB3, and ITGA2B |
| Integrin cell surface interactions | 5 | 0.016 | ICAM1, VWF, ITGB5, ITGB3, and ITGA2B |
| RHO GTPases Activate Formins | 6 | 0.018 | SPC24, KIF2C, CDC20, AURKB, UBE2C, TUBB1, and TUBA1A |
| Separation of Sister Chromatids | 7 | 0.018 | SPC24, KIF2C, CDC20, AURKB, TUBB1, and TUBA1A |
| Cell surface interactions at the vascular wall | 4 | 0.023 | GP6, ESAM, PF4, and TREM1 |
| Intrinsic pathway of fibrin clot formation | 3 | 0.025 | PRKAR2B, TUBB1, TUBA1A, and NTU |
| Hedgehog 'off' state | 4 | 0.025 | VWF, GP1BA, and GP9 |
| Integrin alpha IIb beta 3 signaling | 3 | 0.027 | VWF, ITGB3, and ITGA2B |
| Syndecan interactions | 3 | 0.037 | SDC1, ITGB5, and ITGB3 |
DEGs with a significant change between children with AD and healthy control children (cutoff FC ≥1.5 and FDR <0.05) were used for GO enrichment and pathway analyses using DAVID database. KEGG and Reactome pathway analyses were used to determine the pathways of DEGs between two groups.
Abbreviations: AD, atopic dermatitis; Akt, protein kinase B; Ca2+, calcium ion; DEG, differentially expressed gene; ECM, extracellular matrix; FC, fold change; FCERI, Fc-epsilon receptor; FDR, false discovery rate; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MMP, matrix metalloproteinase; PI3K, phosphoinositide 3-kinase.